Joy Seymour, Vice President, Head of Regulatory Affairs, leads the regulatory function and has accountability for regulatory strategy supporting the advancement of Elicio’s novel immunotherapy programs and oversees Elicio’s collaborations with regulatory health authorities worldwide.
Joy was most recently the Global Regulatory Lead for cellular therapy at Bristol-Myers Squibb where she led the simultaneous submission of four global marketing applications for lisocabtagene maraleucel in Europe, Japan, Switzerland, and Canada, while in parallel as the BLA Lead, secured the US approval for Breyanzi®. During Joy’s tenure at Celgene as the Global Regulatory and US Lead for Abraxane®, she delivered approvals in 11 new countries across multiple oncology indications, overseeing a total of 74 marketing authorizations across geographies, as well as led the submission of Celgene’s first biologic IND in solid and hematologic malignancies.
Joy holds bachelor degrees in biochemistry and human biology from the University of Kansas.
In her free time, Joy tries to spend as much time as reasonable in the water swimming or kayaking, enjoys cooking as the only creative outlet for which she can claim reasonable success, and is a fierce (and usually extremely loud) supporter of the KU Jayhawks.